127 related articles for article (PubMed ID: 11408558)
1. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
2. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
3. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
4. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
5. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
6. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
8. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
9. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.
Li LY; Amidon GL; Kim JS; Heimbach T; Kesisoglou F; Topliss JT; Fleisher D
J Pharmacol Exp Ther; 2002 May; 301(2):586-93. PubMed ID: 11961060
[TBL] [Abstract][Full Text] [Related]
10. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
[TBL] [Abstract][Full Text] [Related]
11. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells.
Gan LS; Moseley MA; Khosla B; Augustijns PF; Bradshaw TP; Hendren RW; Thakker DR
Drug Metab Dispos; 1996 Mar; 24(3):344-9. PubMed ID: 8820426
[TBL] [Abstract][Full Text] [Related]
12. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
13. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
Lin JH; Chiba M; Chen IW; Nishime JA; deLuna FA; Yamazaki M; Lin YJ
Drug Metab Dispos; 1999 Oct; 27(10):1187-93. PubMed ID: 10497146
[TBL] [Abstract][Full Text] [Related]
14. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
15. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
Chiba M; Hensleigh M; Lin JH
Biochem Pharmacol; 1997 Apr; 53(8):1187-95. PubMed ID: 9175724
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
Chan LM; Cooper AE; Dudley AL; Ford D; Hirst BH
J Drug Target; 2004; 12(7):405-13. PubMed ID: 15621665
[TBL] [Abstract][Full Text] [Related]
20. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]